Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics

Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics

Immunogenicity, defined as the ability to provoke an immune response, can be either wanted (i.e., vaccines) or unwanted. The latter refers to an immune response to protein or peptide therapeutics, characterized by the production of anti-drug antibodies, which may affect the efficacy and/or the safet...

Full description

Bibliographic Details
Main Authors: Michel Siegel, Guido Steiner, Linnea C. Franssen, Francesca Carratu, James Herron, Katharina Hartman, Cary M. Looney, Axel Ducret, Katharine Bray-French, Olivier Rohr, Timothy P. Hickling, Noel Smith, Céline Marban-Doran
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Pharmaceutics
Subjects:
immunogenicity
immunomodulation
biotherapeutics
in vitro T cell assay
assay validation
Online Access:https://www.mdpi.com/1999-4923/14/12/2672

Internet

https://www.mdpi.com/1999-4923/14/12/2672

Similar Items